This was the stock's second consecutive day of losses.

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners ...

After a tumultuous year of layoffs and strategic shifts, a Philadelphia biotech company has found a lifeline through a merger ...

Shares of Ocugen Inc. OCGN rallied 5.49% to $1.04 Tuesday, on what proved to be an all-around great trading session for the ...

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.

Investing.com -- Carisma Therapeutics Inc (NASDAQ: CARM) stock jumped 9.1% following the announcement of a definitive merger agreement with OrthoCellix, a wholly-owned subsidiary of Ocugen Inc (NASDAQ ...

Ocugen, a company in the healthcare sector, has experienced a notable decline in its stock price over the past week, dropping by 8.62%. Despite this downturn, analysts like Robert ...

DelveInsight's " Dry AMD Market Insight, Epidemiology And Market Forecast - 2034 " report delivers an in-depth understanding of the dry AMD treatment market, historical and forecasted epidemiology, as ...

The biotech plans to use one-year follow-up data from the Phase II/III trial to support a biologics license application for OCU410ST in 2027.

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

The US FDA has approved Ocugen’s IND amendment to commence a Phase II/III pivotal confirmatory study of OCU410ST.

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients ...